Reducing Inflammatory Signaling from Within the Cell Membrane: Designed Proteins Target TLR4’s Transmembrane Region

After an immune receptor receives an external signal, how does it relay the alarm across the cell membrane and into the cell? This process may also hold new opportunities to suppress inflammation. A team at Scripps Research designed synthetic proteins that target the membrane-embedded region of the innate immune receptor TLR4. In laboratory-cultured human cells, these proteins reduced inflammation-related signaling, providing experimental evidence for targeting a site that is difficult to address with drug design.

The study was published on September 22 in the Proceedings of the National Academy of Sciences (PNAS). TLR4 helps recognize bacteria and initiate immune responses, but its excessive activation is also associated with various inflammatory diseases. The transmembrane region examined in the study not only anchors the receptor in the membrane but may also determine how signals travel into the cell through the angles and arrangements at which proteins contact one another.

The team first tested this idea using a natural protein fragment containing TLR4’s transmembrane region and adjacent portions. Using a screening method in which tagged proteins emit light when they come close together, the researchers observed evidence that the fragment approached and interacted with TLR4, while also measuring a reduction in downstream NF-κB signaling. NF-κB is an important signaling pathway that regulates inflammatory responses. These results support the feasibility of intervening in receptor function from within the membrane and validate the usefulness of the screening platform.

The next challenge was to design proteins that could bind stably to TLR4 within a lipid membrane. The cell membrane environment differs from the aqueous environments inside and outside the cell, and existing structure-prediction tools and AI models may not accurately describe interactions within it. The team therefore used computer-generated three-dimensional structures as a starting point, then applied custom criteria to optimize “nonpolar packing,” allowing the chemical structures at the contact interface between the synthetic protein and the receptor to fit together more closely. They ultimately selected nine candidates for testing in cells.

According to Scripps’ research account, eight of the nine candidates showed signs of binding to TLR4. Design-6 showed the strongest evidence of interaction and markedly reduced NF-κB signaling. It was also less prone to aggregation than the natural TLR4 transmembrane fragment. However, signs of interaction in eight candidates do not mean that all eight have the same inhibitory effect. Reduced aggregation also cannot be taken as direct evidence of greater safety or suitability for use as a drug.

The validation conducted so far used human embryonic kidney cells and cannot yet establish the strategy’s actual effects in disease. The research team noted that further work must confirm the results in immune cells or liver cells more relevant to inflammation and address how to deliver these hydrophobic synthetic proteins into the membranes of target cells. Efficacy in patients has not yet been tested, and the gap between reduced cellular signaling and improved clinical symptoms still needs to be bridged through experiments.

The immediate value of this work is that it gives researchers tools to investigate how TLR4’s transmembrane region controls signaling and establishes a testable method for designing proteins within membranes. Three authors have disclosed a US provisional patent application related to the research. Whether the approach can become an anti-inflammatory therapy depends on subsequent validation in disease models, delivery methods, and safety testing; this cell experiment alone cannot determine that.